---
title: Update Breast Cancer 2023 Part 2 - Advanced-Stage Breast Cancer
date: '2023-11-02'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37916184/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20231102180753&v=2.17.9.post6+86293ac
source: heidelberg[Affiliation]
description: In recent years, a number of new therapies have led to advances in the
  treatment of patients with advanced breast carcinoma. These substances are mainly
  CDK4/6 inhibitors and other substances that can overcome endocrine resistance, oral
  selective estrogen receptor degraders, antibody drug conjugates (ADCs), and PARP
  inhibitors. This review summarizes and evaluates the latest study results that have
  been published in recent months. This includes the overall survival data of the
  ...
disable_comments: true
---
In recent years, a number of new therapies have led to advances in the treatment of patients with advanced breast carcinoma. These substances are mainly CDK4/6 inhibitors and other substances that can overcome endocrine resistance, oral selective estrogen receptor degraders, antibody drug conjugates (ADCs), and PARP inhibitors. This review summarizes and evaluates the latest study results that have been published in recent months. This includes the overall survival data of the ...